--- title: "ACADIA Pharmaceuticals (ACAD) news: class action and settlement" url: "https://aibio.space/companies/acadia-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ACAD class action and settlement news. ACADIA Pharmaceuticals news for investors: Acadia sells Nuplazid for Parkinson's disease psychosis and Daybue for…" --- Desk view · Opinion · Updated Oct 22, 2026 ## Acadia's products carry the quarter while its pipeline story gets harder Acadia is profitable, with revenue guidance raised in August and $956.5 million of cash. The RADIANT result on Sept 24 weakened the pipeline case, and Nuplazid's composition patent runs only into 2030. The business supports itself; the open question is what replaces Nuplazid's growth. Read the full desk view aibio.space Investor Rank · Opinion **5** /10 Neutral view Profitable with $956.5 million of cash, but remlifanserin narrowly missed its phase 2 endpoint and Nuplazid's composition patent runs only to 2030. - **Technology**: 1/2 - **Odds**: 0/2 - **Balance sheet**: 2/2 - **Risk**: 1/2 - **Momentum**: 1/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Mixed.** Two marketed drugs work commercially, while remlifanserin's phase 2 trended better than placebo but narrowly missed its primary endpoint. - **Odds**: **Lower than before.** The 60 mg dose missed at p=0.0603, and Citi cut its success estimate for the drug to 20% from 35%. - **Balance sheet**: **Strong.** $956.5 million in cash and investments, net income of $31.5 million in the second quarter, and no runway concern. - **Main risk**: **Pipeline concentration.** Remlifanserin's phase 3 results carry the growth story beyond Nuplazid's 2030 composition patent expiry. - **Watch next**: **Nov 16 to 19, 2026.** Full RADIANT data at CTAD in Boston. ## Top news on ACADIA 1. 2026-09-11 Legal [Acadia derivative settlement gets preliminary approval as securities class action stays pending](https://aibio.space/news/acadia-derivative-settlement-gets-preliminary-approval-securities/) Nine individuals are named in the derivative suit: Baker, Biggar, Soland, Brege, Davis, Garofalo, Daly, Harrigan and Srdjan (Serge) Stankovic. The class action names Acadia and unnamed officers. 2. 2026-08-05 Legal [Acadia awaits Federal Circuit ruling in Nuplazid patent suits; Zydus trial set for Nov. 2](https://aibio.space/news/acadia-awaits-federal-circuit-ruling-nuplazid-patent-suits-zydus-trial/) Acadia is the plaintiff against Aurobindo, MSN, Teva and Zydus entities. A June 2025 judgment for Acadia is on appeal, and a new Zydus case goes to trial November 2, 2026. 3. 2025-05-20 Legal [Acadia Pharmaceuticals wins Delaware ruling on NUPLAZID formulation patent](https://aibio.space/news/acadia-pharmaceuticals-wins-delaware-ruling-nuplazid-formulation/) A federal court in Delaware ruled for Acadia on infringement and validity of the '721 patent against Aurobindo and MSN entities. The company also signed a lease of 12 years and two months for new Princeton offices. ## Dates **Nov 16 to 19, 2026** Full RADIANT phase 2 data presentation at the CTAD conference in Boston [Source](https://ir.acadia.com/news/news-details/2026/Acadia-Pharmaceuticals-Announces-Phase-3-Enabling-Topline-Results-from-Phase-2-RADIANT-Study-of-Remlifanserin-for-the-Treatment-of-Alzheimers-Disease-Psychosis-ADP/default.aspx) **September to November 2026 (as of Q1 report)** Topline results from the trofinetide Japan trial [Source](https://ir.acadia.com/news/news-details/2026/Acadia-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Reaffirms-2026-Financial-Guidance/default.aspx) **Not dated** EU pricing and reimbursement negotiations for Daybu [Source](https://ir.acadia.com/news/news-details/2026/European-Commission-Approves-DAYBU-trofinetide-as-the-First-and-Only-Treatment-for-Neurobehavioral-Symptoms-of-Rett-Syndrome-in-the-European-Union/default.aspx) **Not dated** Issue of U.S. patent for weight-banded trofinetide dosing (expected to extend protection to March 2041) [Source](https://ir.acadia.com/news/news-details/2026/Acadia-Pharmaceuticals-Announces-Allowance-of-U-S--Patent-Covering-Weight-Banded-Dosing-of-Trofinetide-extending-U-S--patent-protections-to-March-2041/default.aspx) ## The money $956.5 million in cash, cash equivalents and investments at June 30, 2026 (up from $819.7 million at Dec 31, 2025). No runway figure given; the company is profitable. [Source](https://ir.acadia.com/news/news-details/2026/Acadia-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results/default.aspx) Q2 2026 total revenue $308.0 million (up 16%): Nuplazid net sales $183.2 million, Daybue net sales $124.8 million. 2026 revenue guidance $1.24 billion to $1.30 billion. [Source](https://ir.acadia.com/news/news-details/2026/Acadia-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results/default.aspx) ## Risks on the record - The RADIANT phase 2 missed its primary endpoint (p=0.0603, effect size 0.26) and the lead pipeline program now rests on two phase 3 studies at a single dose. [Source](https://ir.acadia.com/news/news-details/2026/Acadia-Pharmaceuticals-Announces-Phase-3-Enabling-Topline-Results-from-Phase-2-RADIANT-Study-of-Remlifanserin-for-the-Treatment-of-Alzheimers-Disease-Psychosis-ADP/default.aspx) - Nuplazid's composition of matter patent protects it into 2030; a formulation patent for the 34 mg capsule runs into 2038. [Source](https://www.businesswire.com/news/home/20250609455203/en/U.S.-Court-of-Appeals-for-the-Federal-Circuit-Affirms-Prior-Delaware-District-Court-Rulings-in-Favor-of-Acadia-in-NUPLAZID-pimavanserin-Composition-of-Matter-Patent) - SG&A is rising faster than revenue ($160.3 million in Q2 vs $133.5 million), with 2026 SG&A guidance of $660 million to $700 million. [Source](https://ir.acadia.com/news/news-details/2026/Acadia-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results/default.aspx) ## Questions investors ask ### What is aibio.space's Investor Rank for ACADIA Pharmaceuticals? 5 out of 10, our neutral view. Profitable with $956.5 million of cash, but remlifanserin narrowly missed its phase 2 endpoint and Nuplazid's composition patent runs only to 2030. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### What happened in Acadia's RADIANT trial? On Sept 24, 2026 Acadia said the phase 2 portion of RADIANT narrowly missed its primary endpoint for remlifanserin 60 mg in Alzheimer's disease psychosis (p=0.0603). A clinical global impression measure reached nominal significance, and phase 3 will continue at 60 mg. [Source](https://ir.acadia.com/news/news-details/2026/Acadia-Pharmaceuticals-Announces-Phase-3-Enabling-Topline-Results-from-Phase-2-RADIANT-Study-of-Remlifanserin-for-the-Treatment-of-Alzheimers-Disease-Psychosis-ADP/default.aspx) ### How much revenue does Acadia make? Acadia reported total revenue of $308.0 million in the second quarter of 2026. Nuplazid brought in $183.2 million and Daybue $124.8 million. The company guides to $1.24 billion to $1.30 billion for 2026. [Source](https://ir.acadia.com/news/news-details/2026/Acadia-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results/default.aspx) ### Is Daybue approved in Europe? Yes. The European Commission approved Daybu (trofinetide) for neurobehavioral symptoms of Rett syndrome in patients aged five and older, Acadia announced on Aug 24, 2026. Pricing and reimbursement negotiations come next, with no launch date given. [Source](https://ir.acadia.com/news/news-details/2026/European-Commission-Approves-DAYBU-trofinetide-as-the-First-and-Only-Treatment-for-Neurobehavioral-Symptoms-of-Rett-Syndrome-in-the-European-Union/default.aspx) ### How long does Nuplazid have patent protection? A Federal Circuit ruling in June 2025 affirmed Nuplazid's composition of matter patent, which provides protection into 2030. A separate formulation patent for the 34 mg capsule runs into 2038. [Source](https://www.businesswire.com/news/home/20250609455203/en/U.S.-Court-of-Appeals-for-the-Federal-Circuit-Affirms-Prior-Delaware-District-Court-Rulings-in-Favor-of-Acadia-in-NUPLAZID-pimavanserin-Composition-of-Matter-Patent) ### How much cash does Acadia Pharmaceuticals have? Acadia held $956.5 million in cash, cash equivalents and investments on June 30, 2026, up from $819.7 million at the end of 2025. It reported second-quarter net income of $31.5 million. [Source](https://ir.acadia.com/news/news-details/2026/Acadia-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results/default.aspx) ### What is the latest ACADIA Pharmaceuticals (ACAD) stock news? Our latest story on ACADIA Pharmaceuticals, dated Sep 11, 2026: "Acadia derivative settlement gets preliminary approval as securities class action stays pending". Nine individuals are named in the derivative suit: Baker, Biggar, Soland, Brege, Davis, Garofalo, Daly, Harrigan and Srdjan (Serge) Stankovic. The class action names Acadia and unnamed officers. [Source](https://aibio.space/news/acadia-derivative-settlement-gets-preliminary-approval-securities/) ### Is ACADIA Pharmaceuticals facing a lawsuit? Our latest legal story, dated Sep 11, 2026: "Acadia derivative settlement gets preliminary approval as securities class action stays pending". Nine individuals are named in the derivative suit: Baker, Biggar, Soland, Brege, Davis, Garofalo, Daly, Harrigan and Srdjan (Serge) Stankovic. The class action names Acadia and unnamed officers. Claims in lawsuits are allegations until a court rules. [Source](https://aibio.space/news/acadia-derivative-settlement-gets-preliminary-approval-securities/) ### What is ACADIA Pharmaceuticals's market cap? We do not publish live share prices. In its annual report, ACADIA Pharmaceuticals Inc. put the market value of shares held by non-affiliates (public float) at $2.30 billion as of Jun 30, 2025. Source ### Is ACADIA Pharmaceuticals a smaller reporting company? SEC records list ACADIA Pharmaceuticals Inc.'s filer category as: Large accelerated filer. Source ### Where is ACADIA Pharmaceuticals headquartered? SEC records list its business address as 12830 EL CAMINO REAL, SAN DIEGO, CA, 92130. Source ### When does ACADIA Pharmaceuticals's fiscal year end? ACADIA Pharmaceuticals Inc.'s fiscal year ends on December 31, per SEC records. Source ### What did ACADIA Pharmaceuticals last file with the SEC? Its most recent filing in our record is an 8-K filed 2026-09-24. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1070494/000119312526401157/d168737d8k.htm) ### What industry is ACADIA Pharmaceuticals in? Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source ### How can I follow ACADIA Pharmaceuticals (ACAD) news? Press Follow on this page to add ACADIA Pharmaceuticals to your Following list, or subscribe to the aibio.space newsletter. We have published 3 stories naming ACADIA Pharmaceuticals so far, in Legal. Source ## Legal and investor matters Checked against ACADIA Pharmaceuticals filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. 1. 2026-08-24 Derivative suit Court preliminarily approves settlement of Acadia stockholder derivative suit Acadia said in an 8-K that on August 24, 2026 the U.S. District Court for the Southern District of California preliminarily approved settlement of the stockholder derivative action Kanner et al. v. Biggar et al., Case No. 3:23-cv-02293-WQH-MSB. The 10-Q says the proposed settlement provides governance reforms and a $1.5 million attorneys' fee award to be paid by the company's insurance carrier. It remains subject to final court approval. U.S. District Court for the Southern District of California · Case 3:23-cv-02293-WQH-MSB · Status: pending [Acadia 8-K filed 2026-09-11](https://www.sec.gov/Archives/edgar/data/1070494/000119312526389400/d143428d8k.htm) 2. 2026-08-05 Class action Acadia securities class action remains pending in San Diego federal court after class certification Acadia's 10-Q filed August 5, 2026 reports that a putative securities class action filed April 19, 2021, City of Birmingham Relief Retirement Systems v. Acadia Pharmaceuticals, Inc., Case No. 21-cv-0762, remains pending. The amended complaint generally alleges that defendants violated Sections 10(b) and 20(a) of the Exchange Act. The court granted class certification on March 11, 2024. The 10-Q says a mandatory settlement conference was scheduled for August 17, 2026 and the final pretrial conference for September 2, 2026. U.S. District Court for the Southern District of California · Case 21-cv-0762 · Status: pending [Acadia 10-Q filed 2026-08-05](https://www.sec.gov/Archives/edgar/data/1070494/000119312526333243/acad-20260630.htm) 3. 2026-07-08 Litigation Court lifts stay in Alger opt-out securities suit against Acadia Acadia reported in its 10-Q that the court lifted on July 8, 2026 its stay of Alger Dynamic Opportunities Fund v. Acadia Pharmaceuticals, Inc., Case No. 24-cv-00451, filed March 7, 2024 by a purported stockholder. The complaint rests on the same allegations as the securities class action. The court had granted in part and denied in part a motion to dismiss on October 31, 2024. A joint case management plan was due August 21, 2026. U.S. District Court for the Southern District of California · Case 24-cv-00451 · Status: pending [Acadia 10-Q filed 2026-08-05](https://www.sec.gov/Archives/edgar/data/1070494/000119312526333243/acad-20260630.htm) 4. 2025-06-09 Litigation Federal Circuit affirms Nuplazid patent ruling and Delaware court backs Acadia Acadia said in an 8-K that on June 9, 2025 the Federal Circuit affirmed a Delaware decision confirming the validity of its Nuplazid '740 composition of matter patent in litigation against MSN. The 10-Q says the district court also issued a final judgment that day in Acadia's favor in the second set of cases against Aurobindo. MSN and Aurobindo appealed on June 16, 2025, and briefing was completed December 19, 2025. U.S. Court of Appeals for the Federal Circuit; U.S. District Court for the District of Delaware · Status: appealed [Acadia 8-K filed 2025-06-10](https://www.sec.gov/Archives/edgar/data/1070494/000119312525138452/d73868d8k.htm) 5. 2025-02-14 Litigation Acadia sues Zydus over proposed 34 mg pimavanserin tablet; trial set for November 2026 Acadia reported in its 10-Q that on February 14, 2025 it filed a complaint against Zydus entities in the U.S. District Court for the District of Delaware alleging infringement of Orange Book-listed Nuplazid patents by Zydus' proposed 34 mg pimavanserin tablet product. On September 9, 2025 Acadia filed an amended complaint alleging Zydus breached a March 31, 2023 settlement agreement. Trial is scheduled to begin November 2, 2026. U.S. District Court for the District of Delaware · Status: pending [Acadia 10-Q filed 2026-08-05](https://www.sec.gov/Archives/edgar/data/1070494/000119312526333243/acad-20260630.htm) ## Pipeline | Program | Indication | Stage | |---|---|---| | Nuplazid (pimavanserin) | Parkinson's disease psychosis | Marketed in the U.S. [Source](https://ir.acadia.com/news/news-details/2026/Acadia-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results/default.aspx) | | Daybue / Daybu (trofinetide) | Rett syndrome | Marketed in the U.S.; EU approval Aug 2026 (ages 5+) [Source](https://ir.acadia.com/news/news-details/2026/European-Commission-Approves-DAYBU-trofinetide-as-the-First-and-Only-Treatment-for-Neurobehavioral-Symptoms-of-Rett-Syndrome-in-the-European-Union/default.aspx) | | Remlifanserin (ACP-204) | Alzheimer's disease psychosis | Phase 2/3 RADIANT: phase 2 missed primary endpoint (p=0.0603); two phase 3 studies continuing at 60 mg; Fast Track [Source](https://ir.acadia.com/news/news-details/2026/Acadia-Pharmaceuticals-Announces-Phase-3-Enabling-Topline-Results-from-Phase-2-RADIANT-Study-of-Remlifanserin-for-the-Treatment-of-Alzheimers-Disease-Psychosis-ADP/default.aspx) | | Remlifanserin (ACP-204) | Lewy body dementia psychosis | Phase 2 ongoing [Source](https://ir.acadia.com/news/news-details/2026/Acadia-Pharmaceuticals-Announces-Phase-3-Enabling-Topline-Results-from-Phase-2-RADIANT-Study-of-Remlifanserin-for-the-Treatment-of-Alzheimers-Disease-Psychosis-ADP/default.aspx) | | Trofinetide | Rett syndrome in Japan | Japan trial, topline expected Sept to Nov 2026 (as of Q1 report) [Source](https://ir.acadia.com/news/news-details/2026/Acadia-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Reaffirms-2026-Financial-Guidance/default.aspx) | Opinion · Devil's advocate ## Fact-check-o-meter Some gaps Acadia called a missed phase 2 primary endpoint "Phase 3 enabling" Acadia's commercial reporting lines up with its 10-Q, and its non-GAAP comparisons are reconciled. The gap is in the Sept. 24 RADIANT release, whose headline and bullets lead with "phase 3 enabling" trends while the registered primary endpoint was missed and the supportive secondary result is nominal. A certified securities class action over an earlier dementia psychosis filing remains pending per the 10-Q. 1. Press release vs filing · weight high Headline frames a primary endpoint miss as phase 3 enabling **The company said:** "Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer's Disease Psychosis (ADP)" [source](https://www.sec.gov/Archives/edgar/data/1070494/000119312526401157/d168737dex991.htm) **The record says:** ClinicalTrials.gov lists a single primary outcome for the RADIANT master protocol: SAPS-H+D total score change from baseline "From baseline to Week 6". The release's own second bullet says the study "Narrowly missed primary endpoint of SAPS H+D (p=0.0603)", with a standardized effect size of 0.26 for 60 mg. [source](https://clinicaltrials.gov/study/NCT06159673) **Our view:** The release does disclose the miss, but only after a headline and lead bullet built on trends. Investors reading headlines alone would not learn that the primary endpoint was missed. 2. Science · weight high Support rests on a nominal secondary and one surviving dose **The company said:** "Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect" [source](https://www.sec.gov/Archives/edgar/data/1070494/000119312526401157/d168737dex991.htm) **The record says:** The release gives the CGI-S-ADP result as "p=0.0077 (nominal)" and says "The 30 mg dose showed minimal improvement across endpoints compared to placebo." Acadia is "implementing amendments to the Phase 3 program, including removing the 30 mg dosage arm." The release gives no patient numbers. ClinicalTrials.gov describes three seamlessly enrolling substudies with an estimated 1,074 participants and primary completion in January 2028. [source](https://clinicaltrials.gov/study/NCT06159673) **Our view:** A nominal p value on a secondary endpoint after a primary miss is hypothesis generating, not confirmation. The phase 3 studies now test a single dose, and full data, including sample sizes, are due at CTAD in November. 3. Press release vs filing · weight low Nuplazid growth headline uses an adjusted base **The company said:** "Second quarter NUPLAZID GAAP net sales of $183 million, up 10% year-over-year on a non-GAAP adjusted basis" [source](https://www.sec.gov/Archives/edgar/data/1070494/000119312526332858/acad-ex99_1.htm) **The record says:** The body of the same release says GAAP Nuplazid sales were "up 9% compared to GAAP net product sales of $168 million for the second quarter of 2025", and it reconciles the adjusted figure to an IRA rebate accrual change. The 10-Q balance sheet shows the same $956 million cash and investments total ($385.0 million cash plus $571.5 million securities). [source](https://www.sec.gov/Archives/edgar/data/1070494/000119312526333243/acad-20260630.htm) **Our view:** This is a small and fully reconciled difference. Financial messaging is otherwise consistent with the 10-Q. 4. Legal and disclosure record · weight medium Certified securities class action is still pending **The record says:** Note 9 of the 10-Q discloses City of Birmingham Relief Retirement Systems v. Acadia Pharmaceuticals, Inc., Case No. 21-cv-0762, filed April 19, 2021 in the U.S. District Court for the Southern District of California. The amended complaint "generally alleges" nondisclosure of "statistical and design deficiencies" in the pimavanserin dementia-related psychosis sNDA. The court certified a class on March 11, 2024, and a final pretrial conference was scheduled for Sept. 2, 2026. An opt-out suit (Alger Dynamic Opportunities Fund, Case No. 24-cv-00451) is also pending, and a derivative suit (Kanner et al v. Biggar et al., Case No. 23-cv-2293) has a proposed settlement with governance reforms and $1.5 million in fees paid by the insurer, subject to court approval. [source](https://www.sec.gov/Archives/edgar/data/1070494/000119312526333243/acad-20260630.htm) **Our view:** These are allegations in complaints. The 10-Q says the company cannot predict the outcome, cannot estimate possible losses and has accrued only attorneys' fees incurred to date. The class action concerns an earlier sNDA for dementia-related psychosis. Documents we compared - [Press release: RADIANT phase 2 topline results (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526401157/d168737dex991.htm) 2026-09-24 - [Notice of proposed settlement of derivative matters (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526389400/d143428dex991.htm) 2026-09-11 - [Press release: second quarter 2026 results (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526332858/acad-ex99_1.htm) 2026-08-04 - [Form 10-Q for quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1070494/000119312526333243/acad-20260630.htm) 2026-08-05 - [ClinicalTrials.gov NCT06159673 (RADIANT master protocol)](https://clinicaltrials.gov/study/NCT06159673) 2026-10-19 This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ACAD on TradingView](https://www.tradingview.com/symbols/NASDAQ-ACAD/). ## SEC filings and registration - **SEC name**: Acadia Pharmaceuticals Inc - **CIK**: 1070494 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ACAD (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 12830 EL CAMINO REAL, SAN DIEGO, CA, 92130 - **Phone**: 858-558-2871 - **Shares outstanding**: 172,305,518 as of 2026-07-28 (10-Q filed 2026-08-05) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1070494/000119312526401157/d168737d8k.htm) filed 2026-09-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1070494/000119312526389400/d143428d8k.htm) filed 2026-09-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1070494/000119312526333243/acad-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1070494/000119312526332858/acad-20260804.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1070494/000119312526248242/d140910d8k.htm) filed 2026-05-29 - [10-Q](https://www.sec.gov/Archives/edgar/data/1070494/000119312526209731/acad-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1070494/000119312526209253/acad-20260506.htm) filed 2026-05-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1070494/000119312526197957/acad-20260427.htm) filed 2026-05-01 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001070494), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/acadia-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ACADIA Pharmaceuticals (ACAD) news: class action and settlement", 2026-10-31, https://aibio.space/companies/acadia-pharmaceuticals/